Document Actions

You are here: FRIAS Events Staudinger Lectures 28th Hermann Staudinger Lecture …

28th Hermann Staudinger Lecture with Nobel Laureate Lou Ignarro

Louis Ignarro by Carlos Barretta (cropped).jpg

Louis J. Ignarro

Molecular and Medical Pharmacology
University of California, Los Angeles

 
 

 

 

Zé Carlos Barretta from São Paulo, Brasil
[CC BY 2.0]

The Road to Stockholm - A Nobel Mission
When Nov 05, 2019
from 04:15 PM to 05:30 PM
Where Albertstraße 17, Anatomy Lecture Hall
Contact Name
Contact Phone +49 (0)761 203-97407
Attendees öffentlich / open to public
Add event to calendar vCal
iCal

The Road to Stockholm - A Nobel Mission

 

Dr. Ignarro is a pharmacologist who has spent over 40 years as a research scientist. In 1998, he was co-recipient of the 1998 Nobel Prize in Physiology or Medicine with Robert F. Furchgott and Ferid Murad for the discovery that nitric oxide (NO) acts as a signaling molecule in the cardiovascular system.

Ignarro is currently professor emeritus of pharmacology at the UCLA School of Medicine's department of molecular and medical pharmacology in Los Angeles.

 

For more information, please see the Nobel Prize website
 

HSL Ignarro

 

Abstract

 

The field of nitric oxide (NO) research has developed in explosive proportions since the discovery of endogenous NO in 1986. The first biologically important actions of NO were vasodilation and inhibition of blood clotting, by mechanisms involving stimulation of cyclic GMP production.  The cyclic GMP system is the principal signal transduction mechanism by which NO elicits many of its physiological effects in mammals.  NO acts as a CNS and peripheral neurotransmitter, where NO facilitates memory, learning, recall and erectile function. Based on these properties of NO, new drugs have been and are being developed to treat hypertension, atherosclerosis, stroke, angina pectoris, heart failure, vascular complications of diabetes, GI ulcers, impotency and other vascular disorders.  The unique properties of NO allow for the opportunity to develop novel drugs for diagnosis, prevention and treatment of a multitude of cardiovascular and other disorders.